Erytech Pharma Inc.

192 articles with Erytech Pharma Inc.

• ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022

  5/24/2022

  ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the availability of the documents for its Annual General Meeting to be held on Friday, June 24, 2022.

• ERYTECH to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that its Chief Executive Officer, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference.

• ERYTECH Provides Business and Financial Update for the First Quarter of 2022

  5/12/2022

  ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business and financial update at the end of March 2022.

• ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar

  4/28/2022

  ERYTECH Pharma announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the “Autorité des Marchés Financiers” and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S.

• ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent

  4/25/2022

  ERYTECH Pharma announced the sale of its U.S. manufacturing facility toCatalent, a leading contract development and manufacturing organization in advanced therapies.

• ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology

  4/6/2022

  ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announces the results from the NOPHO sponsored Phase 2 trial of eryaspase in ALL patients are now published in the British Journal of Haematology.

• ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society

  4/4/2022

  ERYTECH Pharma announced the presentation of its novel red blood cell vesiculation technology at the 24th Meeting of the European Red Cell Society, taking place from April 7 to 11, 2022 in Gazzada Schianno, Italy.

• ERYTECH to Participate in the Upcoming April 2022 Investor Conferences

  3/28/2022

  ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings:

• ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021

  3/11/2022

  ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business update and an update on its cash position at the end of December 2021.

• ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

  2/8/2022

  ERYTECH Pharma announced the allowance of a US patent application covering arginine deiminase encapsulated into red blood cells for the treatment of arginase-1 deficiency, a debilitating rare metabolic disease.

• 

  Clinical Catch-Up: January 24 – January 28

  1/31/2022

  Clinical trial news definitely picked up this final week of January. Here’s a look.

• ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

  1/24/2022

  ERYTECH Pharma announced presentation of results of two trials evaluating eryaspasein advanced pancreatic cancerat the American Society of Clinical Oncology Gastrointestinal Cancers Symposium on January 21, 2022.

• ERYTECH to Participate in the Upcoming January 2022 Virtual Investor Conferences

  1/3/2022

  ERYTECH Pharma announced their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings:

• ERYTECH Announces $7.85 Million Registered Direct Offering

  12/14/2021

  ERYTECH Pharma announced that it has entered into a definitive agreement with Armistice, ahealth-care focused institutional and accredited investor, for the purchase and sale of 769,608units, each Unit consisting of four ordinary shares in the form of American Depositary Shares and three warrants, each to purchase one ordinary share, in a registered direct offering to specified categories of investors, described below.

• ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI

  12/13/2021

  ERYTECH Pharma (Nasdaq & Euronext: ERYP),today announced a summary of its poster presentation at the 2021 ASH Annual Meeting evaluating GRASPA® (eryaspase) in acute lymphoblastic leukemia (ALL) as well as the acceptance of two abstracts evaluating eryaspase in advanced pancreatic cancer at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

• ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors

  11/29/2021

  ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the granting of US patent 11,141,468, covering methods of treating solid tumors by administering methioninase and asparaginase.

• ERYTECH Provides Business and Financial Update for the Third Quarter of 2021

  11/15/2021

  ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business update and an update on its cash position at the end of September 2021.

• ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting

  11/15/2021

  ERYTECH Pharma announced the acceptance of an abstract with the results of its expanded access program evaluating eryaspase in acute lymphoblastic leukemia for poster presentation at the upcoming 2021 American Society of Hematology Annual Meeting, which will be held from December 11-14, 2021, both inAtlanta, Georgiaand virtually.

• ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal

  11/10/2021

  ERYTECH Pharma announced the publicationof amultiparametric characterization of red blood cells after its proprietary technology ERYCAPS®in high impact journal, Acta Pharmaceutica Sinica B.

• ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference

  11/9/2021

  ERYTECH Pharma announced that its CEO, Gil Beyen, will participate in a fireside chat at the 12th Annual Jefferies London Healthcare Conferenceand invites investors to participate in one-on-one meetings both in-person on Tuesday and Wednesday, November 16th/17th or virtually on Thursday and Friday, November 18th/19th.